Background: Patients with food allergy produce high-titer IgE antibodies that bind to mast cells through FcεRI and trigger immediate hypersensitivity reactions on antigen encounter. Food-specific IgG antibodies arise in the setting of naturally resolving food allergy and accompany the acquisition of food allergen unresponsiveness in oral immunotherapy. Objective: In this study we sought to delineate the effects of IgG and its inhibitory Fc receptor, FcgRIIb, on both de novo allergen sensitization in naive animals and on established immune responses in the setting of pre-existing food allergy. Methods: Allergen-specific IgG was administered to mice undergoing sensitization and desensitization to the model food allergen ovalbumin. Cellular and molecular mechanisms were interrogated by using mast cell-and FcgRIIb-deficient mice. The requirement for FcgRII in IgG-mediated inhibition of human mast cells was investigated by using a neutralizing antibody. Results: Administration of specific IgG to food allergy-prone IL4raF709 mice during initial food exposure prevented the development of IgE antibodies, T H 2 responses, and anaphylactic responses on challenge. When given as an adjunct to oral desensitization in mice with established IgE-mediated hypersensitivity, IgG facilitated tolerance restoration, favoring expansion of forkhead box protein 3-positive regulatory T cells along with suppression of existing T H 2 and IgE responses. IgG and FcgRIIb suppress adaptive allergic responses through effects on mast cell function. Conclusion: These findings suggest that allergen-specific IgG antibodies can act to induce and sustain immunologic tolerance
Food allergy is a highly prevalent but intractable immunologic disorder with no established cures and limited treatment options. Oral immunotherapy (OIT), which is currently under development in clinical trials, offers a promising approach for induction of tolerance to food allergens. OIT is performed by oral administration of increasing amounts of the allergenic food over several months. Allergic symptoms are common during the course of therapy and can be troublesome enough to cause safety concerns or discourage completion. Moreover, long-term success rates, defined as maintenance of the food-unresponsive state for 6 months or more after discontinuation of therapy, are in the range of only 15% to 30%, [1] [2] [3] an outcome that suggests that true immunologic tolerance is not fully induced. Adjunctive therapy with omalizumab (anti-IgE) during OIT has been implemented in some trials to reduce symptoms 4 and facilitate more rapid escalation of allergen dosing. [5] [6] [7] A consistent immunologic feature of OIT is the marked increase (several logs) in serum levels of allergen-specific IgG antibodies. Whereas IgE binding to the high-affinity receptor FcεRI triggers degranulation and cytokine production by mast cells and basophils, IgG bound to the inhibitory receptor FcgRIIb counters these effects, suppressing allergic reactions and anaphylaxis, [8] [9] [10] as well as secretion of immunomodulatory cytokines that can exacerbate further reactions by amplifying proallergic T H 2 responses. 11 In B cells simultaneous engagement of FcgRIIb and the B-cell receptor reduces immunoglobulin production, exerting feedback inhibition on allergen-specific IgE synthesis. 12 Both induction of the allergic state in food-sensitive patients and maintenance of tolerance in healthy subjects are orchestrated by allergen-specific T cells. T H 2 cells promote IgE production and mast cell expansion in patients with food allergy; regulatory T (Treg) cells counteract these responses and are essential to the nonresponsive tolerant phenotype in healthy subjects. [13] [14] [15] [16] [17] Food allergy is associated with a reduction in Treg cell numbers and switch to a T H 2-like phenotype, changes that are pathogenic in mice. 18, 19 Allergen-mediated cross-linking of IgE on mast cells is responsible for this disruption in Treg cell formation and can occur directly when FcεRI-driven mast cell cytokines, such as IL-4 and IL-6, divert naive T-cell fate decisions from Treg cells to T H 2 cells. [18] [19] [20] In mice with food allergy undergoing OIT, interference with IgE receptor signaling in mast cells is permissive for the generation of Treg cells and leads to restoration of tolerance. Although Treg cell induction has been associated with the natural outgrowth of food allergy, data on Treg cell induction after OIT have been inconsistent, and it is apparent that OIT does not effectively restore Treg cell function in many patients. 3, 15, 21, 22 Ultimately, it is likely that Treg cells will be essential for long-term oral tolerance 13 and that designing OIT strategies that specifically boost allergen-specific Treg cell generation will be critical to the success of this therapy.
In this study we characterize the effects of food allergenspecific IgG antibodies on emerging and established foodinduced allergic responses. We demonstrate that IgG and FcgRIIb modulate the severity of anaphylactic shock that occurs in sensitized animals on allergen ingestion. We show that in allergy-prone mice administration of allergen-specific IgG before sensitization limits IgE production and regulates T-cell responses, favoring the development of Treg cell over T H 2 cell polarization. Furthermore, in mice with established allergy, combining IgG administration with OIT facilitates the expansion of Treg cell populations and tolerance, which is dependent on the presence of FcgRIIb specifically on mast cells.
METHODS Mice
All mice used in this study were bred and maintained under specific pathogen-free conditions in individually ventilated cages at Boston Children's Hospital. All work was performed under protocols reviewed and approved by the local Institutional Animal Care and Use Committee and Animal Research Children's Hospital. Il4raF709 mice on BALB/c and C57BL/6J backgrounds were the kind gift of Dr Talal Chatila and have been previously described, as have Il4raF709 Kit W-sh mice. 18, 19, 23, 24 FcgRIIb 2/2 (B6;129S-Fcgr2b tm1Ttk /J) mice were purchased from the Jackson Laboratory (Bar Harbor, Me) and subsequently crossed with Il4raF709 mice on the C57BL/6J background. IL-4 receptor (IL-4R) a 2/2 (BALB/c-Il4ra tm1Sz /J) mice were obtained from the Jackson Laboratory.
IgG preparation
Murine ovalbumin (OVA)-specific IgG was prepared from pooled sera from mice immunized intraperitoneally with alum (50 mg of protein precipitated to 1 mg of aluminum hydroxide gel (Sigma Aldrich, St Louis, Mo) on days 0 and 7, followed by 10 mg of protein on days 14 and 21. Control IgG was prepared from mock-immunized mice. Human IgG was prepared from pooled serum samples from patients who had undergone OIT for peanut allergy or from nonallergic donors. IgG was isolated over Nab Protein G Spin Columns (Thermo Scientific, Waltham, Mass), concentrated, dialyzed with Macrosep Advance Centrifugal Devices carrying a 100-kDa cutoff (Pall Corporation, Westborough, Mass), and filter sterilized with 0.2 mmol/L syringe filters (Millex, EMD Millipore, Billerica, Mass). Murine OVA-specific IgG concentrations were determined by means of ELISA, and mice were injected with 100 mg of IgG 1 . Peanut-specific IgG 4 in human IgG preparations was quantified by means of ImmunoCAP on a Phadia 100 (Thermo Scientific, Kalamazoo, Mich).
Food allergen sensitization, desensitization, and anaphylaxis
Mice were sensitized by means of oral gavage with 250 mg of OVA (grade V, Sigma Aldrich) plus 20 mg of cholera toxin (List Laboratories, Campbell, Calif) in 200 mL of PBS once a week for 3 to 8 weeks, as indicated according to procedures we developed. 18, 24 Desensitization was performed in mice previously sensitized as above by means of daily administration of 5 mg of allergen protein administered intragastrically for 3 weeks. Enteral challenge with 150 mg of OVA was performed 7 to 10 days after discontinuation of sensitization or desensitization gavages to elicit anaphylaxis. Where specified, recombinant murine IL-4 (Shenandoah Biotechnology, Warwick, Pa) was administered intraperitoneally at 2 mg per mouse once a week in conjunction with OVA dosing. IL-4 was administered as a purified protein (not a long-lived cytokine/antibody complex) only at times of OVA dosing, and the last dose was given a week before challenge; this protocol was designed to mimic the episodic IL-4 release from mast cells undergoing allergen-driven IgE receptor activation without the potent potentiating effect of IL-4 on anaphylactic severity. 25 
Intestinal leukocyte isolation
Lamina propria leukocytes were isolated from the jejunum, as previously described. 26 
ELISAs
Mouse mast cell protease (MMCP) 1 levels in serum samples were measured according to the manufacturer's instructions (eBioscience, San Diego, Calif). OVA-specific IgE and IgG 1 were assessed, as previously described using clones TOε and TOSG1C6 (BioLegend, San Diego, Calif) as standards. 24 The sandwich ELISA for murine IL-4 was constructed by using 11B11 for capture and biotinylated BVD6-24G2 for detection (BioLegend) with recombinant protein standard from Shenandoah Biotechnology. Murine IL-13 was detected by using paired antibodies from Affymetrix/eBioscience: eBio13A and biotinylated eBio1316H. Human IL-4 was detected by using the antibody pair 8D4-8 and biotinylated MP4-25D2 (BioLegend).
Detection of IL-4 production from murine mast cells was enabled by culture in the presence of azide-free anti-IL-4Ra (10 mg/mL, clone mIL4R-M1; BD Biosciences, Franklin Lakes, NJ) to block cellular uptake of secreted IL-4. Similarly, IL-4 reuptake by human mast cells was inhibited with anti-IL4Ra (clone 25463; R&D Systems, Minneapolis, Minn).
Quantitative PCR
Mast cells were stimulated for 1 hour before RNA extraction by using a Qiagen RNeasy Micro Kit (Qiagen, Hilden, Germany). cDNA was prepared with an iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, Calif), and transcripts were assessed in real time by using TaqMan probes (Applied Biosystems/Thermo Fisher, Waltham, Mass). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a housekeeping gene.
Mast cell culture
Cells were cultured in RPMI-1640 medium supplemented with 10% heatinactivated FCS (Atlanta Biologicals, Lawrenceville, Ga), 1 mmol/L sodium pyruvate, 100 U/mL penicillin, 100 mg/mL streptomycin, 10 mg/mL gentamicin, 1% Minimum Essential Medium nonessential amino acids, 55 mmol/L 2-mercaptoethanol, 10 mmol/L HEPES buffer, and 2 mmol/L L-glutamine (all from Thermo Fisher Scientific), henceforth referred to as complete RPMI. Murine bone marrow-derived mast cells (BMMCs) were cultured from bone marrow progenitors in the presence of recombinant murine IL-3 and stem cell factor (10-20 ng/mL, Shenandoah Biotechnology), with repeated selection for nonadherent cells. Human mast cells were isolated from humanized mice by using immunomagnetic selection for c-Kit-expressing cells and subsequently maintained in recombinant human stem cell factor (50 ng/mL), IL-3 (20 ng/mL), and IL-4 (20 ng/mL). 27 Mast cell phenotypes were confirmed by means of flow cytometry (c-Kit
Murine BMMCs were sensitized for 72 hours with sera from OVA-allergic Il4raF709 mice (1% by volume, 34 ng/mL OVA-specific IgE final concentration) and washed before stimulation. In some cases monoclonal IgG 2a anti-OVA (clone TOSGAA1, BioLegend) was added 4 hours before stimulation. Cells (10 5 cells/well) were stimulated for 48 hours with 250 ng/mL OVA.
Human mast cells were sensitized for 72 hours with IgG-depleted serum from donors with peanut allergy (1% by volume; final concentration, 1.4 kU/L peanut-specific IgE) and washed before stimulation. In some cases anti-CD32 (clone FLI8.26, 10 mg/mL, BD Biosciences), IgG (containing 0.9 mg/L peanut-specific IgG 4 final concentration), or both were added 2 hours before stimulation. Cells (10 5 cells/well) were stimulated for 48 hours with 1 mg/ mL peanut extract. Complete peanut extract was prepared, as previously described. 18 
Mast cell reconstitution
Mast cell-deficient Il4raF709 Kit W-sh mice were injected intraperitoneally with 5 3 10 6 BMMCs 8 and 12 weeks before initiation of sensitization. 18 For reconstitution studies, all mast cells used carried Il4raF709 alleles. Reconstitution of the intestine was assessed by means of flow cytometry.
Flow cytometry
Antibodies for flow cytometry were purchased from BioLegend, unless otherwise stated. 
Statistical analysis
Data were plotted and analyzed in Prism 5.0f software (GraphPad Software, La Jolla, Calif). Anaphylaxis data were analyzed by using repeated-measures 2-way ANOVA; all other data were analyzed with standard ANOVA with Bonferroni posttests between groups. ELISA values for IgE varied across multiple orders of magnitude and thus were subjected to log transformation before statistical analysis; for this purpose, null values were assigned a nominal value corresponding to the limit of detection in the assay. P values are 2-tailed. Data are represented as means 6 SEMs for anaphylaxis curves. Flow cytometric data are depicted as points showing individual mice overlaid with means 6 SEMs. ELISA data are represented as boxand-whisker plots depicting medians, quartiles, and ranges for ex vivo data or as bar charts with means 1 SEMs for in vitro data. In vitro mast cell analyses describe the results of 3 independent cultures.
RESULTS

IgG antibodies prevent allergic sensitization to food
IgG antibodies signaling through the inhibitory IgG receptor FcgRIIb provide a powerful brake on IgE-mediated activation of mast cells and basophils, blocking both degranulation and mediator release in cultured cells and anaphylactic responses in vivo. 8, 11, 28 IgE-mediated mast cell activation elicits not only anaphylactogenic mediator production but also secretion of immunomodulatory cytokines critical to the allergic sensitization process. 18, 29 We hypothesized that IgG-mediated inhibition of such cytokine responses would attenuate both developing and established allergic adaptive responses to food allergens. To test this hypothesis, we used a well-characterized mouse model of food allergy, the Il4raF709 atopic mouse, to investigate the effect of IgG antibodies on development of food allergy. 18, 24 Il4raF709 mice have a strong atopic predisposition and defects in oral tolerance that result from disinhibited IL-4R signaling in mast cells and Treg cells. 26 As a result, dietary exposure of naive animals to food proteins can trigger allergic sensitization, with expansion of intestinal mast cells and a failure to generate suppressive Foxp3
1 Treg cell populations because of IgE-dependent IL-4 production from mast cells. 19 We examined the effect of passive administration of IgG on sensitization to the model allergen OVA in Il4raF709 mice. Administration of IgG purified from OVA-hyperimmunized mice to Il4raF709 mice before enteral sensitization prevented the development of anaphylactic food allergy (Fig 1) . IgG from nonimmune mice did not have this effect. After 4 weeks of gavage sensitization with OVA in combination with the adjuvant cholera toxin, gavage challenge with a high dose of OVA (150 mg) provokes a reproducible loss of core body temperature, which was entirely prevented by the OVA-specific IgG administration (Fig  1, A) . There was a corresponding reduction in mast cell degranulation, as assessed by measurement of challenge-dependent release of MMCP-1 and IL-4 into the serum (Fig 1, C and D) . This is consistent with prior observations that IgG prevents degranulation in cultured mast cells, 9 as well as our prior report that mast cells are an important source of IL-4 in patients with food allergy. 18, 19, 30 IL-4 is an important growth factor for mast cells, 26, [31] [32] [33] and coligation of FcgRIIb with cytokine receptors has been reported to inhibit mast cell growth. 34 Examination of intestinal mast cell burden by means of flow cytometry revealed a marked attenuation of allergen-induced mast cell expansion after IgG administration (Fig 1, E) . Consistent with their reduced systemic IL-4 levels, IgG-treated mice showed impaired induction of serum IgE against OVA (Fig 1, B) , and the dominant intestinal T-cell phenotype shifted from IL-4-producing T H 2 to Foxp3 1 Treg cells (Fig 1, F and G) .
Allergen-specific IgG facilitates desensitization
Although decreases in allergen-specific IgE levels are inconsistent, increases in allergen-specific IgG levels are uniformly observed in immunotherapy protocols, including subcutaneous immunotherapy for aeroallergens and OIT for foods. We reasoned that the high levels of IgG present on completion of OIT could affect the allergic phenotype and that providing similar levels of IgG by means of passive transfer at the inception of desensitization might block IgE-mediated mast cell activation, thereby facilitating the acquisition of tolerance. Therefore we administered specific IgG as an adjunct to oral desensitization in mice with established food allergy. Mice subjected to continued oral administration of allergen still had anaphylaxis on subsequent enteral challenge. However, combining desensitization with specific IgG administration greatly reduced anaphylaxis on challenge (Fig 2, A) . MMCP-1 release into the serum, which is indicative of mast cell degranulation, diminished by approximately 70% in mice treated with specific IgG (Fig 2, B) , and (Fig 1, F) and Treg cell (Fig 1, G) frequencies. Data shown are from one of 3 independent experiments. *P < .05, **P < .01, ***P < .001, and ****P < .0001.
IL-4 release also decreased (Fig 2, C) . These effects were not observed with nonimmune IgG, indicating that allergen specificity is required. As we had observed in the experiments using specific IgG to prevent allergic sensitization, adjunctive administration of specific IgG also reduced the intestinal mast cell burden, bringing it back down to approximately half the level seen in mice that did not receive specific IgG (Fig 2, D) . Although control mice undergoing oral desensitization with OVA exhibited increased IgE production, OVA-specific IgG administration prevented this increase (Fig 2, E) . CD4 1 T cells in OVA-sensitized mice had a Foxp3
1 Treg cell-biased phenotype after specific IgG administration (Fig 2, F) , along with reduced T H 2 frequencies (Fig 2, G) .
Tolerance restoration requires FcgRIIb
IgG can exert its inhibitory effects in several ways, including antigen interception and steric blockade of access to IgE, as well as ligation of cellular inhibitory Fc receptors on immune effector cells. Therefore we investigated the contribution of FcgRIIb signaling in IgG-mediated suppression of allergic sensitization. As previously observed in other systems, loss of FcgRIIb in Il4raF709 mice greatly exacerbated the severity of anaphylactic shock in response to allergen challenge, amplifying a modest 18C to 28C temperature loss on the C57BL/6 background into a substantial 78C decrease (Fig 3, A) . Serum IL-4 levels were decreased after IgG administration in wild-type but not FcgRIIb-deficient mice, and mast cell burden was substantially increased by the loss of FcgRIIb (Fig 3, B and C) . Production of IgE, IgG 2b , and IgA was enhanced in FcgRIIb-deficient mice (Fig 3, D, FcgRIIb-deficient mice exhibited enhanced anaphylactic severity, despite high levels of endogenous IgG production during allergen sensitization (see Fig E1) . This suggested the possibility that IgG:FcgRIIb interactions could be equally critical during Data shown are representative of 3 independent experiments. *P < .05, **P < .01, ***P < .001, and ****P < .0001.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 1 allergen desensitization, in which allergen-specific IgG production typically increases by orders of magnitude. 2, 10, 38 To test this hypothesis, Il4raF709 and Ill4raF709 FcgRIIb 2/2 mice were sensitized to OVA and then subjected to oral desensitization combined with administration of either OVA-specific or nonimmune IgG. After desensitization, Il4raF709 mice carrying functional FcgRIIb continued to exhibit modest hypothermia on allergen challenge (Fig 4, A) . However, those mice treated with aOVA IgG did not exhibit anaphylaxis after challenge. In contrast, mice lacking FcgRIIb expression were not protected by aOVA IgG. Serum IL-4 release was markedly enhanced in the absence of FcgRIIb (Fig 4, B) . Mast cell burden and IgE production were suppressed by IgG administration in wild-type but not FcgRIIb-deficient mice (Fig 4, C and D) . Treg cell frequencies were consistently increased by aOVA IgG administration in Il4-raF709 mice (Fig 4, E) . In animals lacking FcgRIIb, aOVA IgG had no effect on Treg cells, and in fact, Treg cell frequencies were consistently reduced, which is consistent with previous reports on FcgRIIb 2/2 mice (Fig 4, E) . aOVA IgG. Data shown are from one of 2 independent experiments. **P < .01, ***P < .001, and ****P < .0001.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 1 manner (Fig 4, F) . Taken together, these findings support the hypothesis that FcgRIIb mediates critical functions of IgG in attenuating allergic responses.
Mast cell-expressed FcgRIIb contributes to IgG-mediated desensitization
Having established a potent effect of FcgRIIb in both allergenspecific and general Treg cell induction through exposure to food in the gastrointestinal mucosa, we sought to determine the critical cellular effector in this response. Using mast cell-deficient Il4-raF709 Kit W-sh mice, we tested the contributions of mast cells and specifically of mast cell FcgRIIb to IgG-mediated tolerance induction during allergen exposure. Mast cell-deficient mice did not exhibit anaphylaxis after sensitization and challenge, but mice reconstituted with mast cells regained responsiveness, exhibiting modest losses of core body temperature (Fig 5, A) , which is consistent with our prior observations using this model. 18 IgG administration abrogated anaphylaxis in mice engrafted with wild-type mast cells but did not do so in animals reconstituted with FcgRIIb 2/2 mast cells. Among IgG-treated mice, serum IL-4 levels were greater in recipients of FcgRIIb-deficient cells, but we did not consistently observe differences in IgE production (Fig 5, B and C) . Engrafted intestinal mast cell numbers were similar in mice receiving wild-type versus FcgRIIb 2/2 mast cells (Fig 5, D) . However, IgG administration reduced mast cell burden solely when FcgRIIb was present (Fig 5, D, Data shown are from one of 3 independent experiments. *P < .05, **P < .01, ***P < .001, and ****P < .0001.
of FcgRIIb on mast cells had no significant effect on Treg cell frequencies in the lamina propria, except when allergen sensitization was combined with specific IgG administration (Fig 5, E) . Animals enterally exposed to OVA and given OVA-specific IgG exhibited increased intestinal Treg cells when populated with FcgRIIb-sufficient mast cells while failing to expand Treg cells after reconstitution with FcgRIIb-deficient mast cells. T H 2 polarization followed the opposite pattern (Fig 5, F) . Data from these experiments show the importance of mast cell-expressed FcgRIIb in mitigating anaphylaxis and tempering T H 2 bias.
FcgRIIb suppresses mast cell IL-4 secretion
Mast cells secrete copious quantities of cytokines on crosslinking of FcεRI by IgE and allergen. Food allergy in Il4raF709 mice requires rapid production of IL-4 by mast cells, which enhances sensitization by promoting T H 2 polarization and B-cell production of IgE and by disrupting Treg cell generation. 18, 19 Because IgG and FcgRIIb regulated the systemic release of IL-4 on challenge of sensitized mice, we tested the hypothesis that IgG blocks mast cell IL-4 production and that this effect is mediated by FcgRIIb. Coligation of FcgRIIb has been shown to inhibit FcεRI-dependent IL-4 release from murine and human basophils and operates in a similar manner to suppress FcεRI-driven cytokine production in dendritic cells. 11, 39 Detecting IL-4 in supernatants of cultured mast cells has often been challenging and has occasionally generated controversy about their ability to produce the cytokine. This difficulty results at least in part from the rapid reuptake of secreted IL-4 through IL-4Rs, precluding its detection in free secreted form. We reasoned that this IL-4R-mediated reuptake of the cytokine would be absent in IL4Ra 2/2 BMMC cultures or blocked after addition of IL-4Ra-neutralizing antibody, allowing for more efficient detection (see Fig E3 in this article' s Online Repository at www.jacionline. org). Using the IL-4Ra-neutralizing antibody to aid detection, we confirmed that allergen-specific IgG antibodies act in a dose-dependent manner to block IgE:FcεRI-induced production of IL-4 by murine mast cells (Fig 6, A) . This inhibitory effect required mast cell expression of FcgRIIb. A parallel inhibitory effect of IgG was observed with respect to IgE-stimulated murine mast cell production of IL-13 (Fig 6, B) . Human mast cells have also been shown to produce IL-4 40 and have been reported to exhibit FcgRIIb-dependent suppression. 41 Both of these findings are somewhat controversial, and expression of IL-4 and FcgRIIb by human mast cells appears to depend considerably on the source of mast cells used. Because of the difficulties in obtaining primary tissue-resident mast cells, many investigators opt for cell lines or cells cultured in isolation from progenitors. We chose instead to isolate mast cells from humanized mice, 27 in which they would have undergone maturation in the setting of tissue-specific cues, 42 although in a hybrid murine-human environment. Such mast cells express both activating and inhibitory Fcg receptors and upregulate IL-4 on FcεRI cross-linking. Therefore we tested the hypothesis that ligation of FcgRIIb by IgG in human mast cells would also suppress IL-4 production. For this purpose, human mast cells were isolated from humanized mice and sensitized with sera from donors who were highly allergic to peanut containing anti-peanut IgE. When human mast cells were stimulated with peanut extract, mRNA transcripts for IL-4 increased approximately 70-fold (Fig 6, C) . IgG purified from the sera of patients with food allergy who had successfully completed OIT suppressed IL4 expression by about 50%. Antibody blockade of CD32 (FcgRIIa and FcgRIIb) restored IL4 levels, which is consistent with an experiments. *P < .05, **P < .01, ***P < .001, and ****P < .0001.
inhibitory effect of FcgRIIb. Similarly, OIT-derived IgG suppressed secretion of IL-4 protein in a largely CD32-dependent manner (Fig 6, D) .
IL-4 administration overrides aspects of IgG-enforced tolerance
We hypothesized that the attenuated T H 2 response observed in the presence of allergen-specific IgG resulted from FcgRIIbmediated suppression of mast cell IL-4 production. This would predict that administration of exogenous IL-4 should counteract the suppressive effects of exogenous IgG on the adaptive response. To test this, Il4raF709 mice were either (1) sensitized to OVA, (2) sensitized to OVA and given IgG aOVA, or (3) sensitized to OVA and given IgG along with IL-4. As observed in prior experiments, IgG administration suppressed the anaphylactic response to allergen. This effect was largely unaffected by IL-4 supplementation, which is consistent with the continuing suppression of degranulation and anaphylactic mediator release by IgG:FcgRIIb (Fig 7, A) . We did not observe statistically significant alterations in the IgG-mediated suppression of MMCP-1 release or IL-4 release after IL-4 administration (Fig 7, C and D) , which is consistent with the continued ability of IgG to suppress mast cell degranulation. However, IL-4 administration restored intestinal mast cell burden to levels seen in normally sensitized mice (Fig 7, E) . Exogenous IL-4 administration also overrode the IgG-mediated shift from T H 2 to Treg cells (Fig 7, F and G) . These findings suggest that although suppression of anaphylaxis results from a direct effect of IgG:FcgRIIb signals on mast cells, suppression of mast cell growth and T H 2 conversion are secondary effects deriving from FcgRIIb-mediated suppression of IL-4 production.
DISCUSSION
IgE and mast cells are central players in food allergy. They exert dual roles in pathogenesis, both priming the pump for T H 2 responses and IgE production after allergen exposure and triggering acute reactions to allergen challenge. 18, 43 The evidence gathered in this study indicates that high-titer allergen-specific IgG antibodies can inhibit both functions. Our results establish that the inhibitory Fc receptor FcgRIIb is the central mediator of this process and that it potently suppresses allergen-induced anaphylaxis and mast cell-driven modulation of T-cell phenotypes. We now show that supplemental administration of allergen-specific IgG not only prevents allergic sensitization but can also restore a desensitized state with tolerogenic T-cell responses in previously allergic mice. We demonstrate the ability of IgG to suppress IL-4 secretion by both human and mouse FcεRI-expressing cells and show that the diminished levels of IL-4 that exist after IgG administration play a role in the shifting Treg cell/T H 2 cell balance. These findings have the potential to inform our understanding of the successes and failures of OIT because they suggest that the development of higher specific IgG/IgE ratios would be more likely to produce lasting tolerance. Furthermore, we suggest that direct modulation of allergenspecific IgG levels in patients with food allergy can facilitate the restoration of tolerance during OIT while simultaneously decreasing adverse reactions, such as has been already been demonstrated in venom immunotherapy. 44 IgG has a lengthy history associating it with clinical tolerance in allergic pathology. 45, 46 Notable observations from studies of bee venom immunotherapy demonstrated a link between the production of IgG anti-venom antibodies and successful clinical outcomes. 47, 48 A recent multicohort study found a strong association between the production of specific IgG 1 and the development of benign rather than pathologic T H 2 responses to aeroallergens in atopic children. 49 In the context of food allergy, murine models have established the importance of FcgRIIb and IgG in regulating anaphylactic shock. 9, 10, 50 Moreover, the regulatory activity of IgG has recently been demonstrated to underlie the desensitized (nonreactive) state observed in patients who have undergone immunotherapy for food allergies, as well as naturally tolerant patients who exhibit food-specific IgE but do not experience adverse reactions on ingestion.
10,51,52 Interestingly, IgG production to ingested foods, including common food allergens, is in fact the norm in tolerant and unsensitized subjects, 53 which raises the possibility that such IgG might normally preclude the development of allergy. 54 Because IgG, unlike IgE, readily crosses the placenta and is secreted in breast milk, food-specific IgG can be inherited by the immunologically naive infant before ever ingesting the food.
Circulating IgG has access to a range of innate and adaptive effector and regulatory cells distributed throughout the body, including mucosal tissues. In this study we have focused on the role of FcgRIIb on mast cells, but there are multiple Fcg receptors and a variety of effector cells that express them. FcgRIIbmediated suppression has been shown to favor tolerogenic phenotypes in dendritic cells and B cells. [35] [36] [37] 39 The ability of FcgRIIb to influence a wide array of cellular functions derives from the relative simplicity of its mechanism of action. The intracellular portion of FcgRIIb contains an immunoreceptor tyrosinebased inhibitory motif that recruits the inhibitory phosphatases Src homology domain 2-containing inositol phosphatase (SHIP), Shp1, and Shp2, which between them have the ability to dephosphorylate and thus deactivate a substantial range of kinases. In the context of IgE receptor signaling, coaggregation of FcεRI with FcgRIIb allows FcεRI-associated Lyn to phosphorylate FcgRIIb, thus recruiting SHIP to the nascent signaling complex. 55 SHIP can then dampen calcium flux through direct degradation of inositol phosphate, as well as regulating the activity of the phosphoinositide 3-kinase and mitogen-activated protein kinase pathways, thus inhibiting both degranulation and downstream cytokine synthesis. 8, 11, 28, 41, 56 In this way both immediate hypersensitivity and subsequent T-cell polarization can be abrogated.
The inverse correlation between allergen-specific IgG responses and allergic symptoms in clinical cohorts 49 Several investigators have tried to harness the negative signal induced by cross-linking of FcεRI and FcgRIIb to control hypersensitivity reactions. A variety of engineered chimeric proteins designed to cross-link allergen-specific IgE on FcεRI with FcgRIIb have been tested in mouse models of allergy and in some clinical trials. [74] [75] [76] Our findings predict that such constructs might additionally exert immunomodulatory effects. However, such effects would be limited to a single allergen (defined in the construct), whereas the polyclonal and polyspecific IgG response arising in subjects with multiple food allergies would have a more encompassing suppressive effect.
Taken together, the presence of food-specific IgG antibodies in healthy subjects, their induction in patients successfully completing OIT, and the immunomodulatory properties of these antibodies, as demonstrated in this study, suggest that the IgG response might constitute a common and important mechanism in the homeostatic pathways inducing and maintaining immunologic tolerance to foods. Investigating the role of IgG in these settings has the potential not only to more clearly define the regulatory mechanisms at play in physiologic host-food interactions but also point to new approaches to testing for food allergy and predicting clinical sensitivity, as well as innovative strategies for manipulating the allergic response.
We thank Dr Talal Chatila for his expertise and for the use of his Il4raF709 mouse.
Key messages
d Allergen-specific IgG prevents anaphylactic food allergy, including T H 2 immune polarization.
d Allergen-specific IgG can be used to restore a nonresponsive, Treg cell-dominated phenotype in previously allergic mice.
d The inhibitory Fcg receptor FcgRIIb is required for these effects. were cultured for 48 hours, and IL-4 levels in the supernatant were determined by means of ELISA. For IgE/antigen (Ag) stimulation, cells were sensitized with polyclonal IgE aOVA from allergic mouse serum and then stimulated with 1 mg/mL OVA. PI, Phorbol 12,13-dibutyrate and ionomycin (500 ng/mL each); WT, wild-type. *P < .05, ***P < .001, and ****P < .0001, Bonferroni posttest on ANOVA.
